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Abstract
Background:  Novel, uncharacterised proteins represent a challenge in biochemistry and
molecular biology. In this report we present an initial functional characterization of human kidney
predominant protein, NCU-G1.
Results: NCU-G1 was found to be a highly conserved nuclear protein rich in proline with a
molecular weight of approximately 44 kDa. It is localized on chromosome 1 and consists of 6
exons. Analysis of the amino acid sequence revealed no known transcription activation domains or
DNA binding regions, however, four nuclear receptor boxes (LXXLL), and four SH3-interaction
motives in addition to numerous potential phosphorylation sites were found. Two nuclear export
signals were identified, but no nuclear localization signal. In man, NCU-G1 was found to be widely
expressed at the mRNA level with especially high levels detected in prostate, liver and kidney.
Electrophoretic mobility shift analysis showed specific binding of NCU-G1 to an oligonucleotide
representing the footprint 1 element of the human cellular retinol-binding protein 1 gene
promoter. NCU-G1 was found to activate transcription from this promoter and required presence
of the footprint 1 element. In transiently transfected Drosophila Schneider S2 cells, we
demonstrated that NCU-G1 functions as a co-activator for ligand-activated PPAR-alpha, resulting
in an increased expression of a CAT reporter gene under control of the peroxisome proliferator-
activated receptor-alpha responsive acyl-CoA oxidase promoter.
Conclusion: We propose that NCU-G1 is a dual-function protein capable of functioning as a
transcription factor as well as a nuclear receptor co-activator.
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Background
Vitamin A is required for proper cell growth, differentia-
tion and function. These processes depend on expression
of appropriate genes at the right time and place, and in
correct amounts. The biological activity with regard to
vitamin A control of gene expression is carried out by
retinoic acid (all-trans isomer or 9-cis isomer), the ligand
for retinoic acid receptors (RARs and RXRs), which are
members of the nuclear receptor superfamily of ligand-
activated transcription factors [1,2]. Malfunction of vita-
min A regulated genes have been described in various can-
cer types [3-5]. Some human carcinomas were shown to
be affected in this manner due to reduced levels of RAR-
β2, a retinoic acid receptor isoform involved in negative
growth regulation [6].
In addition to suboptimal expression or malfunctioning
of retinoic acid receptors, reduced retinoic acid (RA) activ-
ity may also occur because RA is not available. Expression
of some retinoic acid receptors is itself vitamin A depend-
ent, hence the availability of RA becomes crucial. Most
cells depend on conversion of retinol to RA to satisfy their
needs for this ligand [7]. Retinol (ROH) is taken up from
circulating retinol-binding protein (RBP) or released from
intracellular storage of retinylester and transferred to cel-
lular retinol-binding protein type 1 (CRBP1) which regu-
lates its metabolism. In addition to regulating cellular
uptake of ROH, CRBP1 presents ROH to lecithin:retinol
acyl transferase (LRAT) for esterification and storage in
lipid droplets in the cell cytoplasm or interacts with oxi-
dizing enzymes which convert ROH to RA. Hence, CRBP1
plays an essential role in the regulation of vitamin A con-
trolled genes and maintenance of proper cell health.
In contrast to previous concepts of CRBP1 as an inert
chaperone for ROH, CRBP1 is now viewed as an active
participant in vitamin A metabolism [8-10]. The general
understanding of the mechanisms regulating CRBP1
expression and function, however, is not very comprehen-
sive. It has been reported that retinoids, lipids and serum
factors increase the expression of CRBP1, whereas cAMP
and glucocorticoids reduce expression [11-16]. Presently
it is not known whether any regulation of CRBP1 activity
by way of posttranslational modification is taking place.
We are working to identify regulatory mechanisms con-
trolling CRBP1 expression by identifying novel proteins
interacting with the proximal 5'-region (-567/+104) of the
human CRBP1 gene. In a previous report we identified the
transcription start site and seven DNA elements (FP1 –
FP7) which specifically bind nuclear proteins from liver,
kidney and prostate [17]. Several of the DNA elements
were potential binding sites for novel transcription fac-
tors. Here we report the identification and characterisa-
tion of one such protein, NCU-G1, which interacts
specifically with FP1 and stimulates transcription from
the CRBP1 promoter. In addition, NCU-G1 functions as a
nuclear receptor co-activator by stimulating the transcrip-
tional activity of peroxisome proliferator-activated recep-
tor-alpha (PPAR-alpha).
Results
Cloning of human NCU-G1
Previous studies of the hCRBP1 gene promoter identified
a DNA-element (FP1, +66/+96) that comprises target sites
for both the nuclear factor 1 (NF1) and specificity protein
1 (Sp1) transcription factors [17]. Further studies, using
SDS-PAGE fractionation and partial renaturation of
nuclear proteins, enabled us to detect binding of two
unknown proteins, designated Bp1 and Bp2, to the FP1-
element [18]. Bp1 and Bp2, which compete with both Sp1
and NF1 for binding to the Fp1 element, could be
revealed by exploiting the fact that neither Sp1 nor NF1
renature after SDS-PAGE fractionation and hence do not
bind FP1 in electrophoretic mobility shift assay (EMSA)
[19].
In order to study these proteins in more detail, we used
the One-Hybrid cloning strategy to clone their corre-
sponding cDNAs from an expression library prepared
from human placenta. The FP1 element was used as bait
after some modifications to avoid recognition by NF1 and
Sp1. Screening of the placenta expression library resulted
in isolation of three unique clones one of which con-
tained an insert of 1.7 kb. DNA sequencing of this clone
revealed an open reading frame of 1221 base pairs yield-
ing a protein of 406 amino acids (figure 1A). Blast analysis
identified it as kidney predominant protein, alias NCU-
G1 or C1orf85 homologous to the previously published
mouse NCU-G1 [20]. A search of the human genome
database showed that NCU-G1 is located on chromosome
1, 1q23.1, locus 112770, and has an open reading frame
spanning 6 exons. No human homologues were identi-
fied, indicating that NCU-G1 is unique.
Comparison with NCBI GenBank [21] showed a number
of previously submitted sequences corresponding to
human NCU-G1 (GenBank: NM_144580, BC018757,
BC011575), however, no functional characterization of
this protein has been reported. Database searches includ-
ing other species revealed that mammals, birds, frogs and
certain mosquitos all have an NCU-G1 gene (figure 1A),
whereas  Drosophila melanogaster does not. In rodents
(mouse, rat) the open reading frame (ORF) is 404 amino
acids. The human gene has inserted a leucine after amino
acid 52 and a lysine after amino acid 139. The NCU-G1
gene appears to be highly conserved. Complete conserva-
tion of more than 25% of amino acids is seen from mos-
quito to man, and conservative conservation is found in
all available sequences from worm to man. At the amino
acid level, homologies between man/chimpanzee isBMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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Analysis of the NCU-G1 amino acid sequence Figure 1
Analysis of the NCU-G1 amino acid sequence. Panel A: Comparison of deduced NCU-G1 amino acid sequences from 
various species. Totally conserved amino acids are shown against a black background. Highly conserved amino acids are shown 
against a grey background. The positions of conserved prolines are marked with black bullets. Panel B: Potential functional 
motifs in human NCU-G1.BMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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99.8%, man/rat 79%, man/mouse 79% and rat/mouse
82%. Figure 1A shows that there are highly conserved
regions and distinct areas where variations can occur. The
protein has a high content of proline (9.1%) but no spe-
cific proline-rich regions. However, the proline positions
are well conserved.
To search for information on the structure and function of
the NCU-G1 gene product, a variety of data mining tools
were used. NCU-G1 has a predicted MW of 43.8 kDa and
an acidic pI of 6.1 [22]. The molecular weight was verified
by Western analysis using a polyclonal antibody which we
raised against a 15-amino acid peptide covering the C-ter-
minal sequence (see below, figure 2A). No homologies to
known DNA-binding motifs, transcription activation
domains or regions with enzymatic activity were found.
Somewhat surprising, NCU-G1 has four NR-boxes with
the LXXLL signature sequence [23,24]. Such NR-boxes are
found in a number of transcriptional co-activators, such
as the p160-family of co-activators for which the LXXLL
sequences are characteristic [25,26]. The presence of an
NR-box has been determined as necessary and sufficient
for interaction with nuclear receptors, although both
recruitment and effect on transcription are influenced by
other factors such as the sequences flanking the NR-box,
the ligand types of the nuclear receptor itself and the DNA
response elements present on the target genes. As shown
in figure 1B, the LXXLL-motifs were distributed over the
entire protein. The first NR-box (aa 21–25) is conserved in
all NCU-G1 sequences from man to frog. The second NR-
box (aa 53–57) is unusual being preceded by a proline
residue. This NR-box is found only in the NCU-G1 pro-
tein from man and chimpanzee. One of the inserted
amino acids (aa 53), making up part of the difference
between rodents and man, is the first leucine in NR-box
no. 2 of man. The third NR-box (aa 267–271) is present
in all mammals while the fourth NR-box (aa 390–394) is
found in all mammals except in pig.
Four potential Src-homology 3 (SH3) interacting
domains with the signature sequence PXXP were also
identified in NCU-G1 (figure 1B). According to Cesareni
et al. [27] motif no. 1 (aa 203–206) is a class II motif,
whereas motif no. 4 (aa 298–301) belongs to class I. As
shown for the modulator of non-genomic action of estro-
gen receptor (MNAR), these motifs may bind SH3
domains in c-Src, stabilizing its interaction with a nuclear
receptor and leading to further activation of the ligand-
bound receptor [28]. It may also activate the MAP kinase
signal transduction pathway.
NCU-G1 was initially identified in nuclear fractions and
therefore might be expected to have a nuclear localization
signal (NLS), however, analysis of the NCU-G1 sequence
failed to identify any candidate sequence for an NLS [18].
In spite of this, and as figure 1B indicates, two potential
nuclear export signals (NES) conforming to the
L(X1–3)L(X2–3)LXL formula characteristic of CRM1-medi-
ated transport were found [29]. NES1 is localized in the N-
terminus comprising amino acids 50 to 59 while NES2 is
localized in the C-terminus comprising amino acids 383
to 392. Interestingly, both NES1 and NES2 overlap with
an NR-box, no. 2 and no. 4, respectively.
Human NCU-G1 is a nuclear protein
Our previous studies have shown that NCU-G1 is present
in nuclear extracts but we could not exclude the possibility
that it may also be present in other subcellular compart-
ments [18]. The small size of NCU-G1 would predict an
ability to shuttle between cytosol and nucleus. This
hypothesis was examined by analyzing nuclear and
cytosolic fractions from several cell types by Western blot-
ting.
A polyclonal antibody was raised against a peptide repre-
senting the last fifteen amino acids in the C-terminus of
NCU-G1. Its specificity was verified by Western analysis of
transiently expressed NCU-G1 in Drosophila Schneider
S2 cells which do not express this protein. The predicted
size of NCU-G1 is 43.8 kDa. As shown in figure 2 (panel
A, lane 6) a protein of approximately 45 kDa in size is
detected with this antibody. In contrast, a transiently
expressed truncated version of NCU-G1 lacking exon 6
comprising the C-terminal end of the protein could not be
detected (figure 2A, lane 7). Using this antibody, we
found that NCU-G1 is primarily localized in the nuclei of
JEG3, RPE and 293 cells (figure 2B; lanes 2, 4 and 6,
respectively). The traces of NCU-G1 detected in the
cytosol were probably due to leakage from the nuclei dur-
ing preparation. In order to test this assumption, the
membranes were stripped and analyzed with an antibody
against Sp1 as a marker of nuclear proteins. Figure 2C
shows that some Sp1 is found in the cytosolic fractions,
supporting the notion that partial nuclear rupture during
preparation may account for the NCU-G1 detected in
cytosol.
Human NCU-G1 binds specifically to the FP1-
oligonucleotide
The initial identification of NCU-G1 was based on its abil-
ity to bind FP1 in EMSA. In order to show that our cloned
NCU-G1 represents the proteins we set out to clone, its
ability to bind DNA was studied. Figure 3 shows complex
formation in EMSA between 32P-labeled FP1-oligonucle-
otide and GST-NCU-G1 fusion protein recombinantly
expressed in E. coli. A major band (lane 2) shows specific
binding which is inhibited in the presence of 50-fold
molar excess of unlabeled FP1 oligonucleotide (lane 3).
Unlabeled AP1-, Sp1- or NF1-oligonucleotides at 50-fold
molar excess (lane 4, 5 and 6, respectively) are unable toBMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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Endogenous NCU-G1 is a nuclear protein Figure 2
Endogenous NCU-G1 is a nuclear protein. Panel A: S2 cells were transfected with expression vectors for hNCU-G1 
(pAc-NCU-G1) or its truncated version pAc-hNCU-G1(Δ exon 6). Whole cell extracts (20 μg/lane) were analyzed by West-
ern blotting using preimmune serum (lanes 1 to 3) or an antiserum raised against a C-terminal 15 amino acid peptide (lanes 5 
to 7). Lane 1 and 5: control, untreated S2 cells, lane 2 and 6: S2 cells expressing hNCU-G1, lane 3 and 7: S2 cells expressing 
hNCU-G1(Δ exon6). Panel B: Cytoplasmic and nuclear extracts (20 μg/lane) from JEG3, RPE and 293 cells were size-fraction-
ated on 10% SDS-PAGE gels and analyzed by Western blotting using NCU-G1 antiserum. Lane 1: JEG3 cytosol, lane 2: JEG3 
nuclear extract, lane 3: RPE cytosol, lane 4: RPE nuclear extract, lane 5: 293 cytosol, lane 6: 293 nuclear extract. Panel C: The 
membranes used in panel B were stripped and analyzed with an antibody against Sp1.
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inhibit complex formation. Control GST did not bind the
FP1 oligonucleotide (data not shown).
Human NCU-G1 stimulates transcription from the 
hCRBP1 promoter
The ability of NCU-G1 to interact in EMSA with the FP1-
element of the human CRBP1 promoter prompted us to
analyse whether such interaction might entail an ability to
modulate transcription. The human CRBP1 promoter (-
567/+104 bp) was inserted upstream of the chloramphen-
icol acetyl-transferase (CAT) gene in a reporter vector
(pCAT3) and transiently co-transfected with an expres-
sion vector for NCU-G1 into Drosophila Schneider S2
cells (S2 cells). These cells were chosen in order to avoid
interference with Sp1 and NF1 which also bind to the FP1
element of the hCRBP1 promoter. Although these cells are
not mammalian, S2 cells express transcription factors sim-
ilar to those found in mammalian cells, but they often do
not recognize mammalian proteins or mammalian DNA
consensus elements, resulting in lower background and
less interference [30]. Figure 4A shows that expression of
low levels of hNCU-G1 leads to a 17-fold increase of CAT
expression.
In order to test whether transcriptional induction was
mediated by the FP1 element, we created deletion
mutants of the CRBP1 promoter controlling reporter gene
expression. The expression vector (pOCAT) used in these
experiments has a somewhat higher basal activity result-
ing in the induction by NCU-G1 appearing smaller [17].
Expression of NCU-G1 increased reporter gene expression
by 7.5-fold (fig. 4B). Deletion of FP1 from the full-length
reporter construct (phCRBP1(-483/+69)OCAT) abro-
gated the induction of reporter gene expression by NCU-
G1. Removing most of the promoter region upstream of
the transcription start site but leaving FP1 intact
(phCRBP1(-20/+104)OCAT) did not affect the ability of
NCU-G1 to induce reporter gene expression. Again, a
deletion that removes the FP1 element from this construct
abolishes this induction (phCRBP1(-20/+69)OCAT).
These results demonstrate that the FP1-element is an
absolute requirement for NCU-G1's ability to induce
reporter gene expression from the CRBP1 promoter.
In order to eliminate the possibility of any nuclear recep-
tor (NR)-box contribution to the CRBP1 promoter con-
trolled reporter gene expression, we created mutated
versions of NCU-G1. Single or multiple NR-boxes were
mutated from LXXLL to LXXAA to inhibit interaction with
possible NR-box binding proteins. Figure 4C shows that
mutation of one or more NR-boxes does not affect NCU-
G1's ability to activate reporter gene transcription from
the CRBP1 promoter, confirming that the NR-boxes are
not involved.
Next, we studied the effect of deleting exons or segments
of NCU-G1 on its ability to control reporter gene expres-
sion from the CRBP1 promoter. Figure 4D shows that
deletion of exon 6 actually potentiates NCU-G1's stimula-
tory effect on CAT expression. This exon comprises a
stretch of hydrophobic amino acids (aa 372–394) that
may be involved in attenuating NCU-G1 stimulation of
CAT expression. A deletion mutant lacking just this hydro-
phobic region, however, did not stimulate CAT expression
to the same extent. Deletion of exon 5 and 6, exon 4–6,
exon 3–6 or amino acid 1–81 reduces NCU-G1 stimula-
tory activity to approximately 50% of that of wild-type
NCU-G1. In contrast, deletion of exon 2 results in a com-
plete loss of stimulatory activity, indicating that this
region comprising amino acids 42–126 is important for
NCU-G1 activity.
Human NCU-G1 binds to the FP1-element of the CRBP1  promoter Figure 3
Human NCU-G1 binds to the FP1-element of the 
CRBP1 promoter. NCU-G1 was expressed as a fusion 
protein with GST in E. coli and purified. Interaction between 
GST-NCU-G1 and radiolabeled FP1-oligonucleotide was ana-
lysed by EMSA. Lane 1 shows 32P-labeled FP1 oligonucleotide 
(control). Lane 2 shows complex formation between GST-
NCU-G1 and 32P-labeled FP1 oligonucleotide. Lane 3, 4, 5 
and 6 show complex formation between GST-NCU-G1 and 
32P-labeled FP1 oligonucleotide in the presence of 50-fold 
molar excess of unlabeled FP1 oligonucleotide, Ap1 oligonu-
cleotide, Sp1 oligonucleotide or NF1 oligonucleotide, respec-
tively. Ns = non-specific.
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NCU-G1 mRNA is highly expressed in human liver, kidney 
and prostate
The tissue specific expression of NCU-G1 in man was
investigated at the mRNA-level. Most tissues tested were
found to express NCU-G1 mRNA, however, it was most
abundant in liver, kidney and prostate, with somewhat
lower levels in placenta, ovary and adrenal. In contrast,
expression was low in heart, lung, and skeletal muscle
(data not shown). These results are corroborated by data
reported on the SAGE-express web-site [31].
Human NCU-G1 acts as a co-activator for PPAR-alpha
The presence of four NR-boxes in NCU-G1 prompted us
to study its possible capacity to function as a co-regulator
Human NCU-G1 activates transcription from the hCRBP1 promoter Figure 4
Human NCU-G1 activates transcription from the hCRBP1 promoter. Panel A: S2 cells were co-transfected with 250 
ng pAc5.1/V5-His-LacZ, 350 ng phCRBP1-CAT and increasing amounts (2.5 ng – 50 ng) of pAc-hNCU-G1 as shown in the fig-
ure. Panel B: S2 cells were co-transfected with 250 ng pAc5.1/V5-His-LacZ, 350 ng plasmid expressing CAT under the control 
of various fragments of the hCRBP1 promoter as shown in the figure and 10 ng pAc-hNCU-G1. Panel C: S2 cells were co-
transfected with 250 ng pAc5.1/V5-His-LacZ, 350 ng phCRBP1-CAT and 10 ng pAc-hNCU-G1 either wild-type or carrying 
mutated NR-boxes as shown in the figure. Panel D: S2 cells were cotransfected with 250 ng pAc5.1/V5-His-LacZ, 350 ng 
phCRBP1-CAT and 10 ng pAc-hNCU-G1 either wild-type or carrying various deletions as shown in the figure. Controls show 
expression of CAT in the absence of any NCU-G1. The cells were harvested 48 hrs after transfection. CAT was assayed by 
ELISA and β-galactosidase by enzyme activity. The data represent relative average values (pg CAT/unit β-galactosidase/hr +/- 
SE) from three independent experiments carried out in triplicates.BMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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for nuclear receptors, here represented by PPAR-alpha, in
transient transfections of S2 cells. The rationale for choos-
ing PPAR was the identification of a number of potential
peroxisome proliferator-activated receptor response ele-
ments (PPARE) in the human CRBP1 promoter region,
using "MatInspector" from Genomatix [23]. In addition,
PPAR-beta agonists have been reported to stimulate
CRBP1 expression [15]. The ability of NCU-G1 to stimu-
late PPAR transcriptional activity may therefore be rele-
vant to CRBP1 expression.
We chose to use a reporter gene construct expressing CAT
under control of the rat acyl-CoA oxidase gene promoter
[32], a well-known PPAR-alpha target gene [33]. We first
determined the optimal level of PPAR-alpha to be co-
expressed with NCU-G1 in S2 cells. As shown in figure 5A,
expression of CAT was very low when PPAR-alpha was
expressed only in the presence of the PPAR-alpha agonist
WY14643, nor did expression of NCU-G1 lead to any
increase in reporter gene expression. When co-expressed,
however, a strong induction of reporter gene expression
was observed, indicating that NCU-G1 may function as a
co-activator for PPAR-alpha. Maximal induction using
150 ng of the PPAR-alpha expressing vector increased
reporter gene expression by 11-fold.
Interaction between co-activator NR-boxes and nuclear
receptor AF-2 domains have been shown to require the
ligand-induced conformational change of the latter [28].
Hence, we next sought to determine whether NCU-G1's
ability to co-activate PPAR-alpha controlled reporter gene
expression was ligand-dependent. Figure 5B shows that
this is indeed the case. When both PPAR-alpha and NCU-
G1 were expressed in the absence of the ligand, no CAT
activity beyond the level directed by the pACO-CAT plas-
mid alone could be observed. However, addition of the
agonistic ligand WY14643 increased CAT activity by
approximately 11-fold. This result demonstrates that
NCU-G1's ability to co-activate PPAR-alpha requires lig-
and activation of the nuclear receptor.
We next sought to determine which, if indeed any, of the
four NR-boxes in NCU-G1 is responsible for the observed
co-activation. As shown in figure 5C, mutation of NR-
boxes 2, 3, or 4 lowered the co-activating capacity of NCU-
G1 to approximately 50% of that observed with wild-type
NCU-G1. Mutation of NR-box 1, however, completely
abolished NCU-G1's ability to co-activate PPAR-alpha
induced reporter gene expression, supporting our hypoth-
esis that stimulation of PPAR-alpha controlled reporter
gene expression by NCU-G1 is NR-box mediated. A simi-
lar effect was observed when all four NR-boxes were
mutated. In summary, these results suggest that the mech-
anism of NCU-G1 co-activation of PPAR-alpha transcrip-
tional activity requires an intact NR-box 1 and ligand
mediated activation of the nuclear receptor.
NCU-G1 co-localises with PPAR-alpha in the nucleus
Nuclear receptor co-activators may be divided into a pri-
mary and a secondary group where members of the
former interact directly with nuclear receptors and the lat-
ter interact with members of the primary group [34]. In an
effort to determine which of these groups NCU-G1 may
belong to, its ability to interact with PPAR-alpha was stud-
ied in mammalian as well as yeast two-hybrid systems. No
interaction was detected indicating that NCU-G1 is not a
primary co-activator of this nuclear receptor (data not
shown). The possibility of NCU-G1 being a secondary co-
activator was analysed by confocal fluorescence micros-
copy. HeLa cells were transiently transfected with expres-
sion vectors for EGFP-tagged NCU-G1 and RFP-tagged
PPAR-alpha. As shown in figure 6B RFP-PPAR-alpha is
predominantly localised in the nucleus as expected. In
contrast, as shown in figure 6A the fusion protein NCU-
G1-EGFP is mostly cytosolic. However, some NCU-G1-
EGFP was found in the nucleus at distinct spots which
might indicate transport into the nucleus. Once within the
nucleus, as shown in figure 6C, the few NCU-G1-EGFP
spots co-localise with RFP-PPAR-alpha showing potential
cellular interaction domains for NCU-G1 and PPAR-
alpha.
Discussion
In this report, we describe the cloning and initial charac-
terization of human NCU-G1. Sequence analysis detected
no human homologues, however, NCU-G1 is highly con-
served among species. Our experimental data show that
NCU-G1 binds specifically to the FP1 element of the
CRBP1 gene promoter and activates transcription from
this promoter. Furthermore, NCU-G1 functions as a co-
activator for PPAR-alpha directed reporter gene expression
from the acyl-CoA oxidase promoter.
NCU-G1 as a transcription factor
The identification of NCU-G1 as a DNA-binding protein
suggested that it might be a transcription factor. In accord-
ance with this notion we demonstrate specific binding to
the FP1 element of the CRBP1 promoter. Further, NCU-
G1 is shown to mediate activation of transcription from
the CRBP1 promoter. This transcriptional activity requires
the presence of the FP1 element, suggesting that this DNA
element actually is a target site for this potential transcrip-
tion factor. NCU-G1 is a small protein without recogniza-
ble transcription activation domains or DNA-binding
domains, two important regions of a transcription factor.
Deletion of various exons or segments of NCU-G1 indi-
cated that exon 2 and exon 6 are important for transcrip-
tional activity. Since this protein has no substantial
homology to any characterized protein, novel regionsBMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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Human NCU-G1 functions as a ligand dependent and NR-box dependent co-activator for PPAR-alpha in S2 cells Figure 5
Human NCU-G1 functions as a ligand dependent and NR-box dependent co-activator for PPAR-alpha in S2 
cells. Panel A: S2 cells were transiently transfected with 250 ng pAc5.1V5/His-LacZ, 350 ng of pACO-CAT, and increasing 
amounts of pMT-hPPARalpha, in the presence or absence of 10 ng of pAc-hNCU-G1. Twelve hrs after transfection WY14643 
was added to 20 μM. The cells were harvested 56 hrs after transfection. CAT was assayed by ELISA and β-galactosidase by 
enzyme activity. The data represent relative average values (pg CAT/unit β-galactosidase/hr +/- SE) from three independent 
experiments carried out in triplicates. Panel B: S2 cells were transiently transfected with 250 ng pAc5.1V5/His-LacZ, 350 ng of 
pACO-CAT, together with pAc-hNCU-G1, pMT-hPPAR-alpha and WY14643 as indicated. The cells were treated and pre-
sented as in panel A. Panel C: S2 cells were transiently transfected with 250 ng pAc5.1V5/His-LacZ, 350 ng of pACO-CAT, 150 
ng pMT-hPPAR-alpha as indicated and 10 ng of pAc-hNCU-G1, either wild-type or mutated as indicated in the figure. All cells 
were treated with 20 μM WY14643. The cells were harvested and data presented as in panel A.BMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
Page 10 of 15
(page number not for citation purposes)
with other activities may still exist, however, their identi-
fication and characterization will be the subject of a future
project.
NCU-G1 as a nuclear receptor coactivator
The promoter region of the human CRBP1 gene has a
number of potential PPAREs. Furthermore, PPAR-beta
agonists have been reported to stimulate CRBP1 expres-
sion [15]. The ability of NCU-G1 to stimulate PPAR tran-
scriptional activity may therefore be relevant to CRBP1
expression. Another example of proteins with transcrip-
tional potential via both DNA-binding and protein-pro-
tein interaction is the homeodomain transcription factor
Prox1 [35]. These types of proteins, the activity of which
can be modulated via multiple pathways, appear to play
important roles in various transcriptional networks.
The detection of four LXXLL motifs in the primary
sequence suggested that NCU-G1 might function as a
nuclear receptor co-regulator. This hypothesis was
explored in transient transfections, where NCU-G1 was
found to strongly stimulate transcription from the acyl
CoA-oxidase promoter, a well-known PPAR-alpha target
[33]. This stimulation was shown to be ligand-dependent
and therefore requires the conformational change of the
AF2 domain occuring as a consequence of ligand-binding.
Site-directed mutagenesis of the NCU-G1 NR-boxes
clearly demonstrated that NR-box 1 plays a predominant
role in PPAR-alpha stimulation, since its mutation com-
pletely eliminated NCU-G1's ability to co-activate PPAR-
alpha. NR-box preference in the interaction between
nuclear receptor and co-activator has been described for
other co-activators [36,37]. NR-box 1 is present in all
available sequences from man to frog, indicating that is
important for NCU-G1 function.
Based on the analysis of flanking sequences from both
naturally interacting partners and phage-display assays,
NR-boxes have been organized into four classes according
to the amino acids at position -1 and -2 (the N-terminal L
in the LXXLL motif is arbitrarily designated as +1). All
classes have a hydrophobic amino acid at position -1,
except for motifs that belong to class I which have a basic
amino acid at that position. A proline is usually present at
position -2 in class II motifs whereas class III motifs have
a serine or a threonine at that position. A basic amino acid
is usually found at position -2 in class IV motifs [36-38].
According to these rules we find that NR-box 1 most likely
Human NCU-G1 co-localises with PPAR-alpha in the nucleus Figure 6
Human NCU-G1 co-localises with PPAR-alpha in the nucleus. HeLa cells were transiently transfected with 0.8 μg 
pNCU-G1-EGFP and 0.8 μg pRFP-PPAR-alpha. Twenty hours after transfection WY14643 was added to 2 μM. Six hours later 
the live cells were analysed by confocal fluorescence microscopy. Panel A: Green fluorescence showing subcellular localisation 
of NCU-G1-EGFP. Panel B: Red fluorescence showing subcellular localisation of RFP-PPAR-alpha. Panel C: Merged picture. 
Arrows show foci of co-localisation.
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belongs to class II, although it has a leucine in both posi-
tion -1 and -2. In position -3 and -4 of this NR-box, a pro-
line and a serine are present, respectively, making this a
potential MAP-kinase target site, the phosphorylation of
which may regulate interaction between NCU-G1 and
nuclear receptors.
Mutation of any of the other three NR-boxes resulted in
some reduction of reporter gene expression, hence it can-
not be excluded that they too are of some importance to
the NCU-G1 stimulated PPAR-alpha transcriptional activ-
ity. Alternatively, mutation of NR-boxes 2–4 may lead to
conformational changes resulting in steric hindrance of
the interaction between NR-box 1 and NCU-G1's protein
partners.
Most co-regulators are large proteins with MW > 100 kDa.
The 43.8 kDa NCU-G1 is much smaller, yet it is far from
being the smallest of the presently known co-regulators,
some of which are as small as 16 kDa [37]. Due to its
small size and the fact that no domains with enzyme activ-
ity (such as histone deacetylase) or Q-rich domains medi-
ating transcriptional activation have been identified in
NCU-G1, we hypothesize that it may be a bridging factor.
This notion fits with the presence of three potential SH3-
binding domains. In other proteins such as MNAR, PXXP-
motifs have been shown to mediate interaction with the
SH3-domains in Src-kinases or STAT-proteins [14]. NCU-
G1 may thus serve a function similar to that described for
MNAR and PNRC which stabilize interaction between a
Src-kinase and a nuclear receptor or transcription factor
[28,39]. Such interaction between ER, c-Src and MNAR
leads to phosphorylation of ER triggering stimulation of
the transcriptional activation of ER target genes
[13,14,37,38].
NCU-G1 has two NES but no recognizable NLS, yet
endogenous NCU-G1 is clearly localized in the nucleus of
the three cell types tested (figure 2). Lacking an identifia-
ble NLS sequence, it is presently unclear how NCU-G1
translocates from cytosol to the nucleus. The NLS motif
remains a poorly defined amino acid sequence [40].
Indeed, a number of proteins lacking known NLS have
been shown to enter the cell nucleus [41]. In NCU-G1's
case two mechanisms of nuclear translocation may be
considered. One mechanism is based on size. Since NCU-
G1 is a small protein with a molecular weight below the
cut-off limit for free passage through nuclear pores, NCU-
G1 may enter by simple diffusion. Once inside the
nucleus, NCU-G1 may interact with a nuclear NES-mask-
ing protein serving to hold NCU-G1 in this compartment
as has been reported for p53 [42]. The other mechanism
is the so-called "piggy-back" mechanism where masking
of the NES is involved in nuclear translocation as
described for BRCA1. Here the interacting partner, BARD1
mediates transport into the nucleus [41]. Interaction
between a nuclear receptor and the NES overlapping NR-
boxes in NCU-G1 may also be regarded as a possible
import mechanism for NCU-G1.
Based on NCU-G1's ability to co-activate PPAR-alpha we
had anticipated direct interaction between the two pro-
teins. Unfortunately, despite testing in several systems we
failed to detect any direct interaction between the two pro-
teins, indicating that NCU-G1 is not a primary co-activa-
tor for PPAR-alpha, but rather belongs to the group of
secondary co-activators [34]. The results obtained by tran-
sient expression of the fluorescence tagged NCU-G1-EGFP
and RFP-PPAR-alpha fusion proteins support this notion.
In contrast to the localisation of endogenous NCU-G1
shown in figure 2, microscopy of ectopically expressed
NCU-G1-EGFP showed extended localisation outside the
nucleus. Fusion with EGFP leads to a molecular weight of
approximately 70 kDa, well above the size limit for trans-
fer to the nucleus by diffusion. Since NCU-G1 has no NLS
this may explain why a large fraction of NCU-G1-EGFP is
detected in the extranuclear compartment of the cell. The
3D-structure of NCU-G1 has not been solved, hence, we
cannot exclude that fusion with EGFP disturbs the confor-
mation of NCU-G1 regions important for subcellular traf-
ficking. Although only a small part of expressed NCU-G1-
EGFP enters the nucleus, co-localisation with RFP-PPAR-
alpha is observed. Thus co-localised NCU-G1-EGFP is in a
position to act as co-activator for PPAR-alpha.
Conclusion
The present data suggest that NCU-G1 is a dual-function
nuclear protein serving as a transcription factor as well as
a nuclear receptor co-activator. Both these activities may
contribute to controlling CRBP1 expression.
Methods
Plasmids
The pOTB7-hNCU-G1 from Origene (Rockville, MD,
USA) was used as source of the ORF of NCU-G1. After
digestion with EcoRI/Xho1 NCU-G1 was cloned into the
Drosophila expression vector pAc5.1/V5-His vector (Invit-
rogen, CA, USA), creating pAc-NCU-G1. To create pNCU-
G1-EGFP, the NCU-G1 ORF was excised by EcoR1/Age1
digestion from pOTB7-hNCU-G1 after modification of
this plasmid by site-directed mutagenesis to insert an
Age1 restriction site just before the stop codon of NCU-
G1. The fragment was fused in-frame with EGFP in EcoR1/
Age1 digested pEGFP-N1 (Clontech, CA, USA). The
expression vector pRFP-PPAR-alpha was created by fusion
in-frame of the Xho1/BamH1 digested mouse PPAR-alpha
ORF, produced by PCR using the following primers: 5'-
primer 5'-CTCCTCGAGCTATGGTGGACACAGAGA-3', 3'-
primer 5'-TATGGATCCTCAGTACATGTCTCTGTAGA-3'
and pSG5-mPPAR-alpha as template, into a Xho1/BamH1BMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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digested pRFP-C1 vector (kindly donated by Dr. R. Tsien,
Dept. of Pharmacology, University of California at San
Diego, CA, USA [43].
NR-box mutations
Each NR-box LXXLL-sequence was mutated to LXXAA as
described by the manufacturer using the QuikChange site-
directed mutagenesis kit from Stratagene (La Jolla, CA,
USA). The following primers were used (complementary
antisense-strand sequences are not shown): NR-box 1
mutagenesis 5'-CCCCTGCTCCTTTGGACTGCAGCTCT-
GTTTGCAGCCCCA-3' creating pAc-NCU-G1#1mut, NR-
box 2 mutagenesis 5'-GCCCCCTGCAGAACGCGGCT-
CATATACGGGCAGTGGGC-3' creating pAc-NCU-
G1#2mut, NR-box 3 mutagenesis 5'-GTCTTCCAGTT-
GGACCAGGCAGCGTGGGGCTCCCTCCCA-3' creating
pAc-NCU-G1#3mut, NR-box 4 mutagenesis 5'-
GGCGGCTTGGTTCTGGCGGCGCACCACAAGAAG-
TACTCA-3' creating pAc-NCU-G1#4mut. The pAc-NCU-
G1#1.4mut was constructed by mutation of all four NR-
boxes.
Deletion mutations
All deletions were carried out as site-directed mutations
according to the manufacturer using the QuikChange site-
directed mutagenesis kit from Stratagene (La Jolla, CA,
USA). Complementary antisense-strand sequences are not
shown. Primer 5'-GAATTGCGGCCGTATGGTGGCCAC-
CAAC-3' was used to create pAc-NCU-G1 (Δ aa1-81).
Primer 5'-GACCCGCCAGGTGCTGCTTGAGTTTGAC-3'
was used to create pAc-NCU-G1 (Δ exon 2). Primer 5'-
CTTGTTTTTACCAGGTAAGGCCCGCTCTCTGG-3' was
used to create pAc-NCU-G1 (Δ exon 3-6). Primer 5'-
GGCCTTCAGGTAAGGCCCGCTCT-3' was used to create
pAc-NCU-G1 (Δ exon 4-6). Primer 5'-GCCGTCTTCCAT-
AAGGCCCGCTCTCTGG-3' was used to create pAc-NCU-
G1 (Δ exon 5-6). Primer 5'-CTGGGTGTGGGCTAAG-
GCCCGCTCTCTGG-3' was used to create pAc-NCU-G1 (Δ
exon 6). Primer 5'-CCCCACTAGTCCTGCACCACAA-
GAAG-3' was used to create pAc-NCU-G1(Δ aa372-394).
All mutations were verified by DNA sequencing. The LacZ
expression plasmid pAc5/V5.1-His/LacZ was obtained
from Invitrogen. The pACO-CAT vector was a gift from Dr.
Jonathan Tugwood [32] and pMT-mPPAR-alpha vector
was a gift from Dr. Hilde Nebb, University of Oslo. The
reporter plasmids expressing CAT under the control of
various fragments of the hCRBP1 promoter cloned into
the pOCAT1 vector have been described [17]. The reporter
plasmid phCRBP1-CAT was constructed by insertion of a
Kpn1/Xho1-digested PCR amplified CRBP1 promoter (-
567/+104) fragment into the pCAT3 basic vector
(Promega, Wi, USA). The CRBP1 promoter fragment was
amplified using primers with the following sequences:
forward primer 5'-CCGGTACCGAATTCCTGACCTCAG-
GTGATC-3', reverse primer 5'-GGCTCGAGTTCG-
GGGAGTGACTGGAGCCA-3'. The template was pA21EE,
kindly donated by Magnus Nilsson [44].
Cell cultures
JEG3 cells (36-HTB; ATCC, Boras, Sweden) were grown in
MEM with Earle's salts (BioWhitaker, Verviers, Belgium)
containing 1 g glucose/liter and supplemented with L-
glutamine (2 mM), pyruvate (1 mM), non-essential
amino acids, 10% foetal calf serum (FCS) and antibiotics
(penicillin 100 units/ml, streptomycin 100 μg/ml). Flp-In
293 cells (Invitrogen, CA, USA) were grown in DMEM
(high glucose) supplemented with L-glutamine (2 mM),
10% FCS and antibiotics (penicillin 50 units/ml, strepto-
mycin 50 μg/ml, 100 μg Zeocin/ml). RPE cells (hTERT-
RPE-1, Clontech, CA, USA) were grown in DMEM:F-12
supplemented with glutamine (2 mM), 10% FCS and
antibiotics (penicillin 100 units/ml, streptomycin 100 μg/
ml). HeLa cells were grown in the same medium as Flp-In
293 cells but without Zeocin. All mammalian cells were
grown at 37°C in a humidified atmosphere under 5%
CO2. Drosophila Schneider S2 cells (Drosophila Schnei-
der line 2, # CRL-1963, ATCC) were grown in TC100
medium (PAA Laboratories, Coelbe, Germany) supple-
mented with 10% heat inactivated FCS (PAA laboratories,
#A11-081, insect cell pretested), and antibiotics (penicil-
lin 100 units/ml, streptomycin 100 μg/ml, and fungizone
0.25 μg/ml). The cells were grown at 26°C without CO2.
Electrophoretic mobility shift assay
Double-stranded oligonucleotides representing the FP1
element in the CRBP1 promoter were labelled with
[32P]γATP. For each reaction 3 × 104 cpm labelled probe
was incubated with 2 μg GST-NCU-G1 in the presence or
absence of competing oligonucleotides as described [17].
Oligonucleotide sequences were the following (only the
upper strand is shown): FP1: 5'-GATCCGCCCGCTTGT-
GGCCAACTGGCTCCAGTCAC-3', AP1: 5'-CGCTTGAT-
GACTCAGCCGGAA-3', Sp1: 5'-
GATCATATCTGCGGGGCGGGGCAGACACAG-3', NF1:
5'-GATCTTATTTTGGATTGAAGCCAATATGAG-3'.
Production of GST-NCU-G1 fusion protein
The ORF of NCU-G1 was excised from pOTB7-hNCU-G1
with EcoRI and Xho1 and fused in-frame with glutath-
ione-S-transferase in the pGEX-5X-3 vector (GE Health-
care Bio-Sciences, Uppsala, Sweden). The fusion-protein
was expressed in E. coli BL21(DE3) and purified accord-
ing to the manufacturer's protocol (Invitrogen, CA, USA).
Western analysis
Cells were homogenized and fractionated into nuclear
and cytosolic fractions by the method of Dignam [45].
Twenty micrograms proteins were fractionated on a 10%
SDS-polyacrylamide gel (29:1) and electro-transferred to
a PVDF membrane (Bio-Rad, Hercules, USA). The mem-BMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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brane was blocked for 2 hrs in phosphate buffered saline
containing 5% non-fat milk (PBSM). Primary antibody
incubation for 2 hrs at 25°C was carried out with the
NCU-G1 antiserum diluted 1:1000 in PBSM containing
0.1% Tween 20 (PBSMT). Membranes were washed in
PBS containing 0.1% Tween 20 3 × 5 min., plus 3 × 15
min. with shaking. The secondary antibody (peroxidase-
coupled goat-antirabbit IgG, GE Healthcare Biosciences,
Uppsala, Sweden) was diluted 1:3000 in PBSMT and incu-
bated with the membrane for 2 hrs at 25°C. Membranes
were washed as described above and subjected to a final
wash with PBS. Protein bands were visualized using
Supersignal West Pico reagents from Pierce (Rochford,
USA). The membranes were stripped by incubation for 5
min in 0.2 M NaOH followed by several rinses in PBS
before further analysis.
Northern hybridization
Hybridization was carried out on a human multi-tissue
mRNA filter (Clontech, CA, USA) using a 32P-labeled
NCU-G1 cDNA and beta-actin cDNA as a probes, accord-
ing the manufacturer's instructions. NCU-G1 mRNA
expression levels for each tissue were normalized to the
expression levels of beta-actin and quantified by relative
comparison of the intensity of 32P-labeled NCU-G1
cDNA.
One-hybrid cloning
The MATCHMAKER One-hybrid System (Clontech, CA,
USA) was used to clone NCU-G1. The following oligonu-
cleotide sequence was used as bait: CGCTTGTTTTTTTCT-
GGCTC. This sequence is a modified version of the FP1
element from the hCRBP-1 gene promoter [17] from
which the Sp1 binding site has been truncated and the
NF1 binding site mutated to avoid interference from these
transcription factors. A triplicate version of the oligonu-
cleotide (CGCTTGTTTTTTTCTGGCTCCGCTTGTTTTTT-
TCTGGCTCCGCTTG-TTTTTTTCTGGCTC) was inserted
into the EcoR1-Sac1 site upstream of the HIS3 reporter
gene in the pHISi-vector. A MATCHMAKER cDNA library
from human placenta (Clontech, CA, USA) was used for
screening. Three positive clones were obtained one of
which contained an ORF of 1221 bp. Sequencing was car-
ried out by GATC (Konstanz, Germany) using the Sanger
dideoxy method.
Transfections
For transient transfections of S2 cells, 4 × 105 cells were
plated in 9 cm2 wells (6-well plates) in 2 ml complete
medium. Transfection was carried out the following day
using Fugene 6 (Roche, Mannheim, Germany). Each tis-
sue culture well received a total of 1 μg DNA, comprising
250 ng pAc5.1-LacZ (Invitrogen, CA, USA), 350 ng
reporter vector either pACO-CAT, phCRBP1-CAT or
phCRBP1OCAT, 5–300 ng pMT-PPAR-alpha and 10 ng of
pAc-NCU-G1 wild-type or mutated/truncated. When
expressing PPAR-alpha, CuSO4 was added to 5 μM at the
time of transfection to activate expression from the metal-
lothionine promoter. Twelve hours after transfection, the
PPAR-alpha agonist WY14643 (Sigma-Aldrich, St. Louis,
USA) was added to 20 μM. Fifty-six hours after transfec-
tion the cells were harvested in 1× lysis buffer from the
CAT ELISA kit (Roche, Mannheim, Germany). Expression
of CAT was determined using this kit according to the
manufacturer's instructions. The transfection efficiency
was determined by measuring the γ-galactosidase activity.
Reporter gene expression was calculated as pg CAT/unit β-
galactosidase/hour and presented as relative expression
levels compared to controls which were assigned the value
1.0. The data presented are the mean values of three sepa-
rate transfections carried out in triplicates.
For confocal fluorescence microscopy HeLa cells were
plated in microwell dishes for microscopy (Mattek, MA,
USA) and transfected the following day using Lipo-
fectamine according to the manufacturer's protocol (Inv-
itrogen, CA, USA). Each tissue culture plate received 0.8
μg of pNCU-G1-EGFP and 0.8 μg of pRFP-PPAR-alpha.
Microscopy was carried out 20 hours later.
Antibodies
A peptide comprising the 15 C-terminal amino acids of
hNCU-G1 was chosen for antibody production. Peptide
sequence: LLLHHKKYSEYQSIN. Peptide synthesis, cou-
pling of the peptide to KLH (keyhole limpet hemocy-
anin), injection into rabbits and bleeding was carried out
by MedProbe/Eurogentec (Oslo, Norway). The antisera
were tested in our laboratory. Preimmune serum did not
detect any proteins in a Western analysis of crude nuclear
extracts from transfected S2 cells transiently expressing
NCU-G1. The antiserum detected a protein of approxi-
mately 45 kDa. The polyclonal antibodies directed against
AP1, Sp1 and NF1 were purchased from Santa Cruz (Santa
Cruz, CA, USA).
Yeast two-hybrid interaction
Interaction between PPAR-alpha and NCU-G1 was
assayed using Clontech's Matchmaker GAL4 Two-Hybrid
System. Full-length mPPAR-alpha was PCR-amplifed
using the following primers: forward primer 5'-
TCGACCTTCCCGGGGATCCTGTCTCGAGAAATGGT-
GGACACGGAAAGCCCA-3', reverse primer 5'-ACT-
GAGTCGTCGACGCGGCCGCTTACTAGTACATGTCCCT
GTAGATCTCCTG-3' and pMT-mPPAR-alpha as template.
PPAR-alpha was digested with BamH1/Sal1 and fused in-
frame with the GAL4 activation domain in BamH1/Xho1
digested pGADT7 creating pGADT7-PPAR-alpha. Full-
length hNCU-G1 was PCR-amplified using the following
primers: forward primer 5'-TCGACCTGAATTCATCCCG-
GGATCTCGAGTTATGCGCGGCTCTGTGGAG-3', reverseBMC Molecular Biology 2007, 8:106 http://www.biomedcentral.com/1471-2199/8/106
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primer 5'-ACTGAGTCGTCGACGCGGCCGCTTACTAATT-
TATGGACTGGTACTCTGAGTA-3' and pOTB7-hNCU-G1
as template. NCU-G1 was fused in-frame with the GAL4
binding domain in pGBKT7 after digestion with EcoRI/
Sal1 creating pGBKT7-NCU-G1. The authenticity of
PPAR-alpha, NCU-G1 and their fusion sites were verified
by sequencing. The yeast strains Y187-alpha transformed
with pGADT7-PPAR-alpha and AH109a transformed with
pGBKT7-NCU-G1 were mated by o/n co-incubation in
synthetic complete medium (Clontech) lacking Leu and
Trp before plating onto agar dishes of the same medium.
Positive clones were transferred to agar dishes containing
PPAR-alpha ligand (WY14643, 200 nM) but lacking Leu,
Trp and His to test interaction between PPAR-alpha and
NCU-G1. Y187-alpha transformed with pGADT7-T and
AH109a transformed with pGBKT7-53 were used for pos-
itive controls. Y187-alpha transformed with PGADT7 and
AH109a transformed with pGBKT7 were used for negative
controls.
Confocal fluorescence microscopy
Prior to imaging, the cell medium was changed to DMEM
without phenol red and sodium carbonate (BioWhitaker,
Verviers, Belgium). Image acquisition was performed on
an Olympus Fluoview 1000 at 37°C with an Olympus
PlanApo 60×/1.42 oil objective (Olympus Europa, Ham-
burg, Germany). More than 200 live cells from 5 transfec-
tions were analysed, selecting a wide variety of expression
levels and the co-localisation conclusion is based on this.
List of abbreviations
AF2 activation function domain 2
AP1 Activating protein 1
Bp1 binding protein 1
Bp2 binding protein 2
cAMP adenosine 3',5'-cyclic monophosphate
CAT chloramphenicol acetyl-transferase
CRBP1 cellular retinol-binding protein 1
CRM1 exportin chromosome region maintenance 1
EGFP enhanced green fluorescent protein
FP1 footprint 1
GST glutathione-S-transferase
NCU-G1 kidney predominant protein
NES nuclear export signal
NF1 nuclear factor 1
NLS nuclear localization signal
NR nuclear receptor
PPAR peroxisome proliferators-activated receptor
PVDF polyvinylidene difluoride
RAR retinoid acid receptor
RBP retinol-binding protein
RFP red fluorescent protein
RXR retinoid × receptor
SH3 Src-homology 3
Sp1 specificity protein 1
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